

Supplementary Tables

Table S1 Common and typical symptoms of patients with COVID-19 in selected studies

Symptoms	Mao et al. (n=214)	Guan et al. (n=1099)	Lechien et al. (n=1420)	Marie et al. (n=531)	Argenziano et al. (n=1000)	Docherty et al. (n=20133)
fever	132(61.7)	975(88.7)	645 (45.4)	428 (80.6)	728 (72.8)	12,499/17,452(71.6)
Cough	107(50.0)	745(67.8)	897 (63.2)	455 (85.7)	732 (73.2)	12,896/18,730(68.9)
Dyspnea	-	205(18.7)	697 (49.1)	284 (53.5)	631 (63.1)	12,107/16,999(71.2)
Nausea or	-	55(5.0)	272 (19.2)	-	178 (17.8)	-
Diarrhea	4 (19.2)	-	473 (38.1)	-	236 (23.6)	-
Throat pain	31(14.5)	153(13.9)	751 (52.9)	167 (31.5)	84 (8.4)	-
Myalgia	-	164(14.9)	887 (62.5)	253 (47.6)	268 (26.8)	-
Abdominal pain	10(4.7)	-	270 (19.1)	-	-	-
Headache	-	150(13.6)	998 (70.3)	206 (38.8)	101 (10.1)	-
Loss of smell	-	-	997 (70.2)	134 (25.2)	-	-
Loss of taste	-	-	770 (54.2)	112 (21.1)	-	-

Table S2 Liver function of COVID-19 patients in large sample studies

Author	Region	Type of patients(N)	Liver function	Results	p-Value
Guan et al.	China	Total (1099) Non-severe (926) Severe (173)	AST >40 (U/liter)	168/757 (22.2) 112/615 (18.2) 56/142 (39.4)	-
			ALT >40 (U/liter)	158/741 (21.3) 120/606 (19.8) 38/135 (28.1)	-
			Tbil >17.1 (μmol/L)	76/722 (10.5) 59/594 (9.9) 17/128 (13.3)	-
			ALT (U/L)	34 (23-55) 33.5 (22-55) 36 (24-57)	-
Petrilli et al.	New York	Total (2,729) Non-critical (1,739) Critical (990)	AST (U/L)	46 (32.0-69.0) 42 (29.5-62.0) 53 (36.0-82.0)	-
			ALT (U/L)	27 (18-44) 26 (19-39) 22 (15-35)	0.823
Shi et al.	China	Total (671) Death (62) Survivors (609)	AST (U/L)	29 (21-40) 42 (29-64) 25 (20-32)	<0.001
			Albumin(g/L)	36 (33-38) 33 (30-35) 37 (35-39)	<0.001
			ALT (U/L)	26 (18-41) 25 (17-38) 27 (18-42)	0.003
			AST (U/L)	32 (23-48) 34 (23-52) 31 (23-45)	0.033
Berenguer J.et al	Spain	Total (4035) Death (1131) Alive (2904)	Albumin(g/L)	35 (32-39) 34 (30-38) 36 (32-40)	<0.001
			Tbil(mg/dL)	0.50 (0.37-0.80) 0.56 (0.39-0.87) 0.50 (0.37-0.71)	<0.001
			ALT (U/L)	24.78 (18.50) 23.88 (17.45) 28.50 (22.01)	0.024
			AST (U/L)	26.36 (16.49) 23.87 (11.62) 36.63 (26.60)	<0.001
Lee, J. Y. et al	South Korea	Total (694) Mide case (557) Severe case (137)	Albumin(g/dL)	4.00 (0.48) 4.12 (0.39) 3.53 (0.50)	<0.001

Note: AST, alanine aminotransferase; ALT, aspartate aminotransferase; Tbil, total bilirubin; PND, primary end point (a composite end point of admission to intensive care unit, use of invasive mechanical ventilation and death); ICU, intensive care unit.

Table S3 Complications of COVID-19 patients in large sample studies

Author	Region	Study	n	ARDS (%)	ARF (%)	AMI (%)	HF (%)	AKI (%)	Shock
Shi et al.	Wuhan,	CSS	671	61(9.1)	56(8.4)	20(3.1)	12(1.8)	-	4(0.6)
Guan et al.	China	-	1,099	37(3.4)	-	-	-	6(0.5)	12(1.1)
Zhou et al.	Wuhan,	RCS1	191	-	59(30.8)	33(17.3)	33(17.3)	28(14.7)	38(19.9)
Argenziano et al.	New York, US	RCS2	850	299(35.2)	-	8(0.9)	24(2.8)	288(33.9)	-

Note: CSS, cross-sectional study; RCS1, retrospective cohort study; RCS2, retrospective case series; ARDS, Acute respiratory distress syndrome; ARF, Acute respiratory failure; AMI, Acute myocardial injury; HF, heart failure; AKI, acute kidney injury.